DGAP-Adhoc: bmp media investors AG: Strong third quarter

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Oct 23, 2013 at 5:15 AM

DGAP-Adhoc: bmp media investors AG: Strong third quarter leads to positive nine-months result

bmp media investors AG / Key word(s): Quarter Results 23.10.2013 11:00 Dissemination of an Ad hoc announcement according to Â§ 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- bmp media investors AG: Strong third quarter leads to positive nine-months result - Net profit for Q1-Q3/2013 of EUR 0.9 million - Net asset value (NAV) of 95 cent/share after 87 cent/share in previous year Berlin, 23.10.2013 - Today, the private equity company bmp media investors AG (ISIN DE0003304200) is releasing its nine-months figures for 2013 in accordance with IFRS. Revenue from sales of investments amounted to just under EUR 0.4 million (previous year: EUR 0.0 million). Thanks to a strong third quarter with a profit of EUR 1.3 million (previous year: EUR -0.2 million), net profit for the period amounted to EUR 0.9 million (EUR 0.05/share) and was thus considerably higher than the figure from the same period of the previous year of EUR -2.4 million (EUR -0.13/share). The sale of mbr Targeting GmbH announced on 29 August 2013 did not take effect until 1 October 2013, meaning that both the revenue and the purchase price inflow from the transaction are attributable to the fourth quarter. However, the income generated from the sale is already included in the revaluation amount in the third quarter. Net asset value (NAV), which corresponds to IFRS shareholders' equity, amounted to EUR 17.9 million as of 30 September 2013 (previous year: EUR 16.3 million) or EUR 0.95/share (previous year: EUR 0.87/share). The equity ratio was 99% (previous year: 93%). As of 30 September 2013, liquid funds including marketable securities totalled EUR 5.4 million (previous year: EUR 8.0 million). Bank balances decreased from EUR 3.0 million to EUR 1.2 million. This is primarily due to the further expansion of the portfolio. The media and marketing services portfolio consisted of 18 investments as of 30 September 2013. One or two new investments are to be made in the fourth quarter, but no further sales of investments are planned before the end of the year. The Executive Board continues to expect a positive annual result. The nine-month report is to be published on 29 November 2013 at www.mediainvestors.com --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: For further information: Corinna Riewe Investor Relations criewe@bmp.com Phone: +49-30-20 30 5 567 Fax: +49-30-20 30 5 555 bmp media investors AG, SchlÃ¼terstraÃ?e 38, D-10629 Berlin http://www.mediainvestors.com International securities identification number (ISIN): DE0003304200 This ad hoc report represents neither an offer nor a request for an offer for the purchase of securities to be submitted - especially not in the USA and not in countries or jurisdictions in which an offer, a request for an offer for the purchase of securities to be submitted or the sale of securities would not be permitted under the prevailing Securities Law without prior registration or listing. This ad hoc report represents neither an offer for the sale of shares made out to the bearer nor a request for an offer for the purchase of shares to be submitted. It is for information purposes only. 23.10.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: bmp media investors AG SchlÃ¼terstraÃ?e 38 10629 Berlin Germany Phone: +49 (0)30 20 305-0 Fax: +49 (0)30 20 305-555 E-mail: ir@bmp.com Internet: www.mediainvestors.com ISIN: DE0003304200 WKN: 330420 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, DÃ¼sseldorf, Hamburg, MÃ¼nchen, Stuttgart; Warschau End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

LEGO Mashes Star Wars and Marvel for Fans' Delight

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

NARUTO Card Game Set for June 2027 Global Launch

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

AI Drives Major Time Savings in Endoscopy Tech

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...